Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Reviews in Endocrine and Metabolic Disorders
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2023

30.01.2023

Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond

verfasst von: Wei Yu, De Xie, Tetsuya Yamamoto, Hidenori Koyama, Jidong Cheng

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Hyperuricemia is a metabolic disease caused by purine nucleotide metabolism disorder. The prevalence of hyperuricemia is increasing worldwide, with a growing trend in the younger populations. Although numerous studies have indicated that hyperuricemia may be an independent risk factor for insulin resistance, the causal relationship between the two is controversial. There are few reviews, however, focusing on the relationship between uric acid (UA) and insulin resistance from experimental studies. In this review, we summarized the experimental models related to soluble UA-induced insulin resistance in pancreas and peripheral tissues, including skeletal muscles, adipose tissue, liver, heart/cardiomyocytes, vascular endothelial cells and macrophages. In addition, we summarized the research advances about the key mechanism of UA-induced insulin resistance. Moreover, we attempt to identify novel targets for the treatment of hyperuricemia-related insulin resistance. Lastly, we hope that the present review will encourage further researches to solve the chicken-and-egg dilemma between UA and insulin resistance, and provide strategies for the pathogenesis and treatment of hyperuricemia related metabolic diseases.
Literatur
1.
Chen Y, Luo L, Hu S et al. The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review. Crit Rev Food Sci Nutr. 2022:1–26.
2.
Liu L, Lou S, Xu K, et al. Relationship between lifestyle choices and hyperuricemia in chinese men and women. Clin Rheumatol. 2013;32:233–9.PubMedCrossRef
3.
Koo BS, Jeong HJ, Son CN, et al. Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a korean general population of 172,970. Korean J Intern Med. 2021;36:S264–72.CrossRef
4.
Huang J, Ma ZF, Zhang Y, et al. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. Glob Health Res Policy. 2020;5:52.PubMedPubMedCentralCrossRef
5.
Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and Decadal Trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71:991–9.PubMedPubMedCentralCrossRef
6.
Sofue T, Nakagawa N, Kanda E, et al. Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan chronic kidney Disease Database (J-CKD-DB). PLoS ONE. 2020;15:e0240402.PubMedPubMedCentralCrossRef
7.
Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in thai adults receiving annual health exams. Arch Med Res. 2006;37:883–9.PubMedCrossRef
8.
9.
Yu W, Cheng JD. Uric acid and cardiovascular disease: An update from molecular mechanism to clinical perspective. Front Pharmacol. 2020;11:582680.
10.
Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851–65.PubMedPubMedCentralCrossRef
11.
Ponticelli C, Podestà MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 2020;98:1149–59.PubMedCrossRef
12.
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380–90.PubMedCrossRef
13.
Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76:1870–82.PubMedCrossRef
14.
Kim K, Kang K, Sheol H et al. The association between serum uric acid levels and 10-year cardiovascular disease risk in non-alcoholic fatty liver disease patients. Int J Environ Res Public Health. 2022;19:1042.
15.
Xie D, Zhao H, Lu J, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320:E1032–43.PubMedCrossRef
16.
Zhang Q, Ma X, Xing J, et al. Serum uric acid is a mediator of the association between obesity and incident nonalcoholic fatty liver disease: a prospective cohort study. Front Endocrinol (Lausanne). 2021;12:657856.PubMedCrossRef
17.
Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain. 2009;132:377–82.PubMedCrossRef
18.
Pellecchia MT, Savastano R, Moccia M, et al. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: a 4-year follow-up study. J Neural Transm (Vienna). 2016;123:1399–402.PubMedCrossRef
19.
Chen C, Li X, Lv Y, et al. High blood uric acid is associated with reduced risks of mild cognitive impairment among older adults in China: a 9-Year prospective cohort study. Front Aging Neurosci. 2021;13:747686.PubMedPubMedCentralCrossRef
20.
Wang Q, Zhao H, Gao Y, et al. Uric acid inhibits HMGB1-TLR4-NF-kappaB signaling to alleviate oxygen-glucose deprivation/reoxygenation injury of microglia. Biochem Biophys Res Commun. 2021;540:22–8.PubMedCrossRef
21.
Alam AB, Wu A, Power MC, et al. Associations of serum uric acid with incident dementia and cognitive decline in the ARIC-NCS cohort. J Neurol Sci. 2020;414:116866.PubMedPubMedCentralCrossRef
22.
Latourte A, Soumaré A, Bardin T, et al. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 2018;77:328–35.PubMedCrossRef
23.
24.
Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am. 2007;91:1063–77.
25.
Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176:108–16.PubMedCrossRef
26.
Han T, Lan L, Qu R, et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertension. 2017;70:703–11.PubMedCrossRef
27.
Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25–9.PubMed
28.
Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63:924–9.PubMedCrossRef
29.
McCormick N, O’Connor MJ, Yokose C, et al. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization. Arthritis Rheumatol. 2021;73:2096–104.PubMedPubMedCentralCrossRef
30.
Lu J, Dalbeth N, Yin H, et al. Mouse models for human hyperuricaemia: a critical review. Nat Rev Rheumatol. 2019;15:413–26.PubMedCrossRef
31.
Lu J, Hou X, Yuan X, et al. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. Kidney Int. 2018;93:69–80.PubMedCrossRef
32.
Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chin J Endocrinol Metab. 2020;36:1–13.
33.
Hao Y, Li H, Cao Y, et al. Uricase and horseradish peroxidase hybrid CaHPO(4) nanoflower integrated with transcutaneous patches for treatment of hyperuricemia. J Biomed Nanotechnol. 2019;15:951–65.PubMedCrossRef
34.
Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69:1036–44.PubMedCrossRef
35.
Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol. 2018;261:183–8.PubMedCrossRef
36.
Kuwabara M, Hisatome I, Niwa K, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension. 2018;71:78–86.PubMedCrossRef
37.
Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018;278:226–31.PubMedCrossRef
38.
Ma J, Sheng Y, Lao Z, et al. Hyperuricemia is associated with androgenetic alopecia in men: a cross-sectional case-control study. J Cosmet Dermatol. 2020;19:3122–6.PubMedCrossRef
39.
Salem S, Mehrsai A, Heydari R, Pourmand G. Serum uric acid as a risk predictor for erectile dysfunction. J Sex Med. 2014;11:1118–24.PubMedCrossRef
40.
Chen YF, Lin HH, Lu CC, et al. Gout and a subsequent increased risk of erectile dysfunction in men aged 64 and under: a nationwide cohort study in Taiwan. J Rheumatol. 2015;42:1898–905.PubMedCrossRef
41.
Long H, Jiang J, Xia J, et al. Hyperuricemia is an independent risk factor for erectile dysfunction. J Sex Med. 2016;13:1056–62.PubMedCrossRef
42.
Abdul Sultan A, Mallen C, Hayward R, et al. Gout and subsequent erectile dysfunction: a population-based cohort study from England. Arthritis Res Ther. 2017;19:123.PubMedPubMedCentralCrossRef
43.
Wang W, Jing Z, Liu W et al. Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta-analysis. Andrologia. 2022:e14384.
44.
Totaro M, Dimarakis S, Castellini C, et al. Erectile dysfunction in hyperuricemia: a prevalence meta-analysis and meta-regression study. Andrology. 2022;10:72–81.PubMedCrossRef
45.
Hill MA, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766.PubMedCrossRef
46.
Lipina C, Hundal HS. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. Diabetologia. 2011;54:1596–607.PubMedCrossRef
47.
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234:8152–61.PubMedCrossRef
48.
Saltiel AR. Insulin signaling in health and disease. J Clin Invest. 2021;131:e142241.
49.
50.
51.
Zhu J, Sun L, Yang J, et al. Genetic predisposition to type 2 diabetes and insulin levels is positively associated with serum urate levels. J Clin Endocrinol Metab. 2021;106:e2547-56.PubMedCrossRef
52.
Hu X, Rong S, Wang Q, et al. Association between plasma uric acid and insulin resistance in type 2 diabetes: a mendelian randomization analysis. Diabetes Res Clin Pract. 2021;171:108542.PubMedCrossRef
53.
54.
Nishikawa T, Nagata N, Shimakami T, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10:815.PubMedPubMedCentralCrossRef
55.
Ng HY, Leung FF, Kuo WH, et al. Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome. Clin Exp Pharmacol Physiol. 2021;48:1603–12.PubMedCrossRef
56.
Rocic B, Vucic-Lovrencic M, Poje N, et al. Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells. Bioorg Med Chem Lett. 2005;15:1181–4.PubMedCrossRef
57.
Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic beta cells. Mol Cell Endocrinol. 2013;375:89–96.PubMedCrossRef
58.
Lu J, He Y, Cui L, et al. Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic beta-cell death in uricase-deficient male mice. Diabetes. 2020;69:1149–63.PubMedPubMedCentralCrossRef
59.
Hu Y, Zhao H, Lu J, et al. High uric acid promotes dysfunction in pancreatic beta cells by blocking IRS2/AKT signalling. Mol Cell Endocrinol. 2021;520:111070.PubMedCrossRef
60.
Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447:707–14.PubMedCrossRef
61.
Yuan H, Hu Y, Zhu Y, et al. Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells. Mol Cell Endocrinol. 2017;443:138–45.PubMedCrossRef
62.
Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–69.PubMedPubMedCentralCrossRef
63.
Liu C, Zhou XR, Ye MY, et al. RBP4 is associated with insulin resistance in hyperuricemia-induced rats and patients with hyperuricemia. Front Endocrinol (Lausanne). 2021;12:653819.PubMedCrossRef
64.
Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925–32.PubMedCrossRef
65.
He F, Wang M, Zhao H, et al. Autophagy protects against high uric acid-induced hepatic insulin resistance. Mol Cell Endocrinol. 2022;547:111599.PubMedCrossRef
66.
Tanaka Y, Nagoshi T, Takahashi H, et al. URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice. Mol Metab. 2022;55:101411.PubMedCrossRef
67.
Zhi L, Yuzhang Z, Tianliang H, et al. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. PLoS ONE. 2016;11:e0147737.PubMedPubMedCentralCrossRef
68.
Jiao Z, Chen Y, Xie Y, et al. Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. J Cell Mol Med. 2021;25:6733–45.PubMedPubMedCentralCrossRef
69.
Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28:3197–204.PubMedCrossRef
70.
Tassone EJ, Cimellaro A, Perticone M, et al. Uric acid impairs insulin signaling by promoting Enpp1 binding to insulin receptor in human umbilical vein endothelial cells. Front Endocrinol (Lausanne). 2018;9:98.PubMedCrossRef
71.
Yu W, Chen C, Zhuang W, et al. Silencing TXNIP ameliorates high uric acid-induced insulin resistance via the IRS2/AKT and Nrf2/HO-1 pathways in macrophages. Free Radic Biol Med. 2022;178:42–53.PubMedCrossRef
72.
Zhao H, He F, Lu J, et al. Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway via IRS2-proteasome degradation. Front Immunol. 2022;13:931087.PubMedPubMedCentralCrossRef
73.
Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with β-cell function in type 2 diabetes. Diabetes Metab Res Rev. 2018;34:e3001.PubMedCrossRef
74.
Tang W, Fu Q, Zhang Q et al. The association between serum uric acid and residual β -cell function in type 2 diabetes. J Diabetes Res 2014;2014:709691.
75.
Zhong X, Zhang D, Yang L, et al. The relationship between serum uric acid within the normal range and β-cell function in chinese patients with type 2 diabetes: differences by body mass index and gender. PeerJ. 2019;7:e6666.PubMedPubMedCentralCrossRef
76.
Kutoh E, Wada A, Kuto AN, Hayashi J. Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: a potential link between uric acid and pancreatic β-cell function. Int J Clin Pharmacol Ther. 2019;57:590–5.PubMedCrossRef
77.
Yu P, Huang L, Wang Z, et al. The Association of serum uric acid with Beta-cell function and insulin resistance in nondiabetic individuals: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:2673–82.PubMedPubMedCentralCrossRef
78.
Martinez-Sanchez FD, Vargas-Abonce VP, Guerrero-Castillo AP, et al. Serum uric acid concentration is associated with insulin resistance and impaired insulin secretion in adults at risk for type 2 diabetes. Prim Care Diabetes. 2021;15:293–9.PubMedCrossRef
79.
Fernandez-Chirino L, Antonio-Villa NE, Fermin-Martinez CA et al. Elevated serum uric acid is a facilitating mechanism for insulin resistance mediated accumulation of visceral adipose tissue. Clin Endocrinol (Oxf). 2022;96:707–18.
80.
Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40:1367–93.PubMedCrossRef
81.
Feuvray D, Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab. 2008;34(Suppl 1):3–9.CrossRef
82.
Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care. 2007;10:142–8.PubMedCrossRef
83.
Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014;114:1713–21.PubMedCrossRef
84.
Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16:15–24.PubMedCrossRef
85.
Palazzuoli A, Ruocco G, De Vivo O, et al. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction. Am J Cardiol. 2017;120:1146–50.PubMedCrossRef
86.
Pavlusova M, Jarkovsky J, Benesova K, et al. Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry. Clin Cardiol. 2019;42:720–7.PubMedPubMedCentralCrossRef
87.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.PubMedCrossRef
88.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24.PubMedCrossRef
89.
Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–29.PubMedCrossRef
90.
Wilcox CS, Shen W, Boulton DW et al. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018;7:e007046.
91.
Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458–62.PubMedCrossRef
92.
Xin Y, Guo Y, Li Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis. Saudi J Biol Sci. 2019;26:421–6.PubMedCrossRef
93.
Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–33.PubMedCrossRef
94.
Honka H, Solis-Herrera C, Triplitt C, et al. Therapeutic manipulation of myocardial metabolism: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2022–39.PubMedCrossRef
95.
Dyck JRB, Sossalla S, Hamdani N, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17–31.PubMedCrossRef
96.
Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107:1032–8.
97.
Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: a “Thrifty Substrate” hypothesis. Diabetes Care. 2016;39:1108–14.PubMedCrossRef
98.
Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–22.PubMedCrossRef
99.
Zhou H, Wang S, Zhu P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335–46.PubMedCrossRef
100.
Hawley SA, Ford RJ, Smith BK, et al. The Na+/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65:2784–94.PubMedCrossRef
101.
Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection. Pflugers Arch. 2022;474:83–98.PubMedCrossRef
102.
103.
Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924–67.PubMedCrossRef
104.
Cassano V, Crescibene D, Hribal ML et al. Uric acid and vascular damage in essential hypertension: role of insulin resistance. Nutrients. 2020;12:2509.
105.
106.
107.
DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard lecture 2009. Diabetologia. 2010;53:1270–87.PubMedPubMedCentralCrossRef
108.
Mukhuty A, Fouzder C, Kundu R. Fetuin-A secretion from beta-cells leads to accumulation of macrophages in islets, aggravates inflammation and impairs insulin secretion. J Cell Sci. 2021;134:jcs258507.
109.
Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016;23:87.PubMedPubMedCentralCrossRef
110.
Imai Y, Dobrian AD, Weaver JR, et al. Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes Metab. 2013;15(Suppl 3):117–29.PubMedPubMedCentralCrossRef
111.
Imai Y, Dobrian AD, Morris MA, Nadler JL. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol Metab. 2013;24:351–60.PubMedPubMedCentralCrossRef
112.
113.
114.
Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015;72:4111–26.PubMedCrossRef
115.
Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. 2011;11:788–98.PubMedCrossRef
116.
Rehman A, Pacher P, Haskó G. Role of macrophages in the endocrine system. Trends Endocrinol Metab. 2021;32:238–56.PubMedCrossRef
117.
Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:93.PubMedCrossRef
118.
Yu W, Liu W, Xie et al. High level of uric acid promotes atherosclerosis by targeting NRF2-mediated autophagy dysfunction and ferroptosis. Oxid Med Cell Longev. 2022;2022:9304383.
119.
Kimura Y, Yanagida T, Onda A, et al. Soluble uric acid promotes atherosclerosis via AMPK (AMP-Activated protein Kinase)-Mediated inflammation. Arterioscler Thromb Vasc Biol. 2020;40:570–82.PubMedCrossRef
120.
Qayyum N, Haseeb M, Kim MS, Choi S. Role of thioredoxin-interacting protein in diseases and its therapeutic outlook. Int J Mol Sci. 2021;22:275422.
121.
Thielen LA, Chen J, Jing G, et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. Cell Metab. 2020;32:353–65.PubMedPubMedCentralCrossRef
122.
Zhang W, Xu P, Li JY. The crucial role of thioredoxin interacting protein in the liver insulin resistance induced by di (2-ethylhexyl) phthalates. Food Chem Toxicol. 2022;164:113045.PubMedCrossRef
123.
Zhang QY, Pan Y, Wang R, et al. Quercetin inhibits AMPK/TXNIP activation and reduces inflammatory lesions to improve insulin signaling defect in the hypothalamus of high fructose-fed rats. J Nutr Biochem. 2014;25:420–8.PubMedCrossRef
124.
Li S, Eguchi N, Lau H, Ichii H. The role of the Nrf2 signaling in obesity and insulin resistance. Int J Mol Sci. 2020;21:6973.
125.
Yagishita Y, Uruno A, Fukutomi T, et al. Nrf2 improves leptin and insulin resistance provoked by hypothalamic oxidative stress. Cell Rep. 2017;18:2030–44.PubMedCrossRef
126.
Chartoumpekis DV, Ziros PG, Psyrogiannis AI, et al. Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes. 2011;60:2465–73.PubMedPubMedCentralCrossRef
127.
Meakin PJ, Chowdhry S, Sharma RS, et al. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol. 2014;34:3305–20.PubMedPubMedCentralCrossRef
128.
Liu Z, Dou W, Ni Z, et al. Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF-κB in mice fed a high-fat diet. Mol Med Rep. 2016;14:1323–31.PubMedCrossRef
129.
130.
Buhl ES, Jessen N, Pold R, et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 2002;51:2199–206.PubMedCrossRef
131.
Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3:403–16.PubMedCrossRef
132.
Lan P, Romero FA, Wodka D, et al. Hit-to-lead optimization and discovery of 5-((5-([1,1’-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid (MK-3903): a novel class of benzimidazole-based activators of AMP-activated protein kinase. J Med Chem. 2017;60:9040–52.PubMedCrossRef
133.
Liu Y, Jurczak MJ, Lear TB, et al. A Fbxo48 inhibitor prevents pAMPKalpha degradation and ameliorates insulin resistance. Nat Chem Biol. 2021;17:298–306.PubMedPubMedCentralCrossRef
134.
Rheinheimer J, de Souza BM, Cardoso NS, et al. Current role of the NLRP3 inflammasome on obesity and insulin resistance: a systematic review. Metabolism. 2017;74:1–9.PubMedCrossRef
135.
Hull C, Dekeryte R, Buchanan H, et al. NLRP3 inflammasome inhibition with MCC950 improves insulin sensitivity and inflammation in a mouse model of frontotemporal dementia. Neuropharmacology. 2020;180:108305.PubMedCrossRef
136.
Chen X, Zhang D, Li Y, et al. NLRP3 inflammasome and IL-1β pathway in type 2 diabetes and atherosclerosis: friend or foe? Pharmacol Res. 2021;173:105885.PubMedCrossRef
137.
Sun K, Wang J, Lan Z, et al. Sleeve gastroplasty combined with the NLRP3 inflammasome inhibitor CY-09 reduces body weight, improves insulin resistance and alleviates hepatic steatosis in mouse model. Obes Surg. 2020;30:3435–43.PubMedCrossRef
138.
Chinta PK, Tambe S, Umrani D, et al. Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice. Can J Physiol Pharmacol. 2022;100:272–81.PubMedCrossRef
139.
Kitada M, Koya D. Autophagy in metabolic disease and ageing. Nat Rev Endocrinol. 2021;17:647–61.PubMedCrossRef
140.
Zhou W, Ye S. Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy. Cell Biol Int. 2018;42:1282–91.PubMedCrossRef
141.
Zhang D, Ma Y, Liu J, et al. Metformin alleviates hepatic steatosis and insulin resistance in a mouse model of high-fat diet-induced nonalcoholic fatty liver disease by promoting transcription factor EB-dependent autophagy. Front Pharmacol. 2021;12:689111.PubMedPubMedCentralCrossRef
142.
Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–62.PubMedCrossRef
143.
Nono Nankam PA, Bluher M. Retinol-binding protein 4 in obesity and metabolic dysfunctions. Mol Cell Endocrinol. 2021;531:111312.PubMedCrossRef
144.
Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol. 2009;5:682–93.PubMedCrossRef
145.
Di Paola R, Caporarello N, Marucci A, et al. ENPP1 affects insulin action and secretion: evidences from in vitro studies. PLoS ONE. 2011;6:e19462.PubMedPubMedCentralCrossRef
146.
Yang B, Xin M, Liang S, et al. New insight into the management of renal excretion and hyperuricemia: potential therapeutic strategies with natural bioactive compounds. Front Pharmacol. 2022;13:1026246.PubMedPubMedCentralCrossRef
147.
Zhang X, Nie Q, Zhang Z et al. Resveratrol affects the expression of uric acid transporter by improving inflammation. Mol Med Rep. 2021;24:564.
148.
Sang M, Du G, Hao J, et al. Modeling and optimizing inhibitory activities of Nelumbinis folium extract on xanthine oxidase using response surface methodology. J Pharm Biomed Anal. 2017;139:37–43.PubMedCrossRef
149.
Xu K, Liu S, Zhao X, et al. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. Biomed Pharmacother. 2019;110:844–9.PubMedCrossRef
150.
Yang S, Cao S, Li C, et al. Berberrubine, a main metabolite of berberine, alleviates non-alcoholic fatty liver disease via modulating glucose and lipid metabolism and restoring gut microbiota. Front Pharmacol. 2022;13:913378.PubMedPubMedCentralCrossRef
151.
Zhou YJ, Xu N, Zhang XC, et al. Chrysin improves glucose and lipid metabolism disorders by regulating the AMPK/PI3K/AKT signaling pathway in insulin-resistant HepG2 cells and HFD/STZ-induced C57BL/6J mice. J Agric Food Chem. 2021;69:5618–27.PubMedCrossRef
152.
Kim SM, Imm JY. The effect of chrysin-loaded phytosomes on insulin resistance and blood sugar control in type 2 diabetic db/db mice. Molecules. 2020;25:550325.
153.
Chang YH, Chiang YF, Chen HY et al. Anti-inflammatory and anti-hyperuricemic effects of chrysin on a high fructose corn syrup-induced hyperuricemia rat model via the amelioration of urate transporters and inhibition of NLRP3 inflammasome signaling pathway. Antioxidants (Basel). 2021;10:564.
154.
Liu W, Chen X, Ge Y, et al. Network pharmacology strategy for revealing the pharmacological mechanism of pharmacokinetic target components of San-Ye-Tang-Zhi-Qing formula for the treatment of type 2 diabetes mellitus. J Ethnopharmacol. 2020;260:113044.PubMedCrossRef
155.
Guo Y, Yu Y, Li H, et al. Inulin supplementation ameliorates hyperuricemia and modulates gut microbiota in Uox-knockout mice. Eur J Nutr. 2021;60:2217–30.PubMedCrossRef
156.
Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34:39–58.PubMedCrossRef
157.
Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23:716–24.PubMedCrossRef
158.
Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiol (Bethesda). 2016;31:283–93.
159.
Zhang W, Wang T, Guo R, et al. Variation of serum uric acid is associated with gut microbiota in patients with Diabetes Mellitus. Front Cell Infect Microbiol. 2021;11:761757.PubMedCrossRef
160.
161.
Quirós PM, Langer T, López-Otín C. New roles for mitochondrial proteases in health, ageing and disease. Nat Rev Mol Cell Biol. 2015;16:345–59.PubMedCrossRef
162.
Villalobos-Labra R, Subiabre M, Toledo F, et al. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. Mol Aspects Med. 2019;66:49–61.PubMedCrossRef
163.
Ouyang R, Zhao X, Zhang R et al. FGF21 attenuates high uric acid–induced endoplasmic reticulum stress, inflammation and vascular endothelial cell dysfunction by activating Sirt1. Mol Med Rep. 2022;25:35.
164.
Yan M, Chen K, He L, et al. Uric acid induces cardiomyocyte apoptosis via activation of calpain-1 and endoplasmic reticulum stress. Cell Physiol Biochem. 2018;45:2122–35.PubMedCrossRef
165.
Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94:1114–25.PubMedCrossRef
166.
Li S, Zhao F, Cheng S, et al. Uric acid-induced endoplasmic reticulum stress triggers phenotypic change in rat glomerular mesangial cells. Nephrol (Carlton). 2013;18:682–9.
167.
Ebrahimi R, Pasalar P, Shokri H et al. Evidence for the effect of soluble uric acid in augmenting endoplasmic reticulum stress markers in human peripheral blood mononuclear cells. J Physiol Biochem. 2022;78:343–53.
168.
169.
Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425–40.PubMedCrossRef
Metadaten
Titel
Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond
verfasst von
Wei Yu
De Xie
Tetsuya Yamamoto
Hidenori Koyama
Jidong Cheng
Publikationsdatum
30.01.2023
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2023
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-023-09787-4

Weitere Artikel der Ausgabe 2/2023

Reviews in Endocrine and Metabolic Disorders 2/2023 Zur Ausgabe

ReviewPaper

The hallmarks of cancer… in pituitary tumors?

ReviewPaper

The immune microenviroment in somatotropinomas: from biology to personalized and target therapy

Correction

Correction to: Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment

ReviewPaper

How does Hashimoto’s thyroiditis affect bone metabolism?

ReviewPaper

Endocrine responses of the stress system to different types of exercise

ReviewPaper

Rare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise